← Leaderboards
Kenneth Cusi
South Texas Veterans Health Care System
$3,842,769
Attributed
$6,886,801
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,886,801 · 2
VA$0 · 1
By mechanism
U01$4,566,048 · 1
R01$2,320,753 · 1
I01$0 · 1
Top collaborators
- Christopher E Forsmark14 shared
- Steven J Hughes14 shared
Others in their field
Top investigators on “Insulin Resistance”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- C Ronald Kahn · Joslin Diabetes Center$58,520,009
- Leonardo Trasande · New York University School Of Medicine$54,198,824
- Walter N Kernan · Yale University$53,085,019
- Jose A Luchsinger · Columbia University Health Sciences$36,610,547
- Domenico Accili · Columbia University Health Sciences$31,951,136
Research focus
Insulin ResistanceClinical ResearchDiabetes MellitusLeadResourcesCross-Sectional StudiesInsulinAreaMortalityEarly DiagnosisBiological MarkersNon-Insulin-Dependent Diabetes MellitusChronicPrevalencePancreasChronic PancreatitisProtocols DocumentationMalignant Neoplasm Of PancreasAcute PancreatitisPancreatitisCohortChronic PainDiabeticMetabolic
Grant awards (23)
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$437,436
U01 · FY2024 · DK
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH$538,644
R01 · FY2023 · DK · contact PI
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$455,662
U01 · FY2023 · DK
PROCEED + DETECT Year 9 supplement patient care costs$135,000
U01 · FY2023 · DK
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH$554,963
R01 · FY2022 · DK · contact PI
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$455,662
U01 · FY2022 · DK
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$90,400
U01 · FY2022 · DK
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH$595,695
R01 · FY2021 · DK · contact PI
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$455,662
U01 · FY2021 · DK
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH$631,451
R01 · FY2020 · DK · contact PI
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$455,662
U01 · FY2020 · DK
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS$90,400
U01 · FY2020 · DK
U01-Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers$359,850
U01 · FY2019 · DK
Administrative Supplement (NoD)$127,845
U01 · FY2019 · DK
U01-Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers$373,553
U01 · FY2018 · DK
U01-Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers$388,805
U01 · FY2017 · DK
U01-Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers$382,431
U01 · FY2016 · DK
U01-Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers$357,680
U01 · FY2015 · DK
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment$0
I01 · FY2014 · VA · contact PI
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment$0
I01 · FY2013 · VA · contact PI
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment$0
I01 · FY2013 · VA · contact PI
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment$0
I01 · FY2011 · VA · contact PI
NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment$0
I01 · FY2009 · VA · contact PI